| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5277009
Max Phase: Preclinical
Molecular Formula: C17H11N5O
Molecular Weight: 301.31
Associated Items:
Representations
Canonical SMILES: N#Cc1cccc2c1n1cncc1c(=O)n2Cc1cccnc1
Standard InChI: InChI=1S/C17H11N5O/c18-7-13-4-1-5-14-16(13)22-11-20-9-15(22)17(23)21(14)10-12-3-2-6-19-8-12/h1-6,8-9,11H,10H2
Standard InChI Key: NLXINISEACDUMD-UHFFFAOYSA-N
Associated Targets(Human)
GABA receptor alpha-1 subunit 399 Activities
GABA receptor alpha-5 subunit 699 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 301.31 | Molecular Weight (Monoisotopic): 301.0964 | AlogP: 1.96 | #Rotatable Bonds: 2 |
| Polar Surface Area: 75.98 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 4.81 | CX LogP: 1.00 | CX LogD: 1.00 |
| Aromatic Rings: 4 | Heavy Atoms: 23 | QED Weighted: 0.57 | Np Likeness Score: -1.35 |
References
| 1. Károlyi BI, Potor A, Kapus GL, Fodor L, Bobok A, Krámos B, Magdó I, Bata I, Szabó G.. (2023) Novel imidazo[1,5-a]quinoxaline derivatives: SAR, selectivity and modeling challenges en route to the identification of an α5-GABAA receptor NAM., 80 [PMID:36549396] [10.1016/j.bmcl.2022.129107] |
Source
Source(1):